New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
07:34 EDTNSTGNanoString launches nCounter PanCancer Pathways Panel
NanoString Technologies announced the launch of the nCounter PanCancer Pathways Panel, a highly-multiplexed, digital gene expression assay that offers a way for translational researchers to investigate cancer biology across all major cancer pathways. A growing body of research has demonstrated that a pathway-based approach to the analysis of gene expression provides a framework for understanding the changes between the biology of different cancers and cancer subtypes. From a single tube, the PanCancer Pathways Panel simultaneously analyzes of all of the key cancer pathways: PI3K, STAT, MAPK, TGF, Notch, Hedgehog, Wnt, Apoptosis, Cell Cycle, RAS, Chromatin Modification, Transcriptional Regulation and DNA Damage Control. Processing samples on the nCounter Analysis System takes just 15 minutes of hands-on time and generates reproducible data, representing a solution for studying cancer.
News For NSTG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 8, 2014
16:07 EDTNSTGNanoString updates Prosigna FDA labeling
NanoString Technologies announced that the FDA has cleared a labeling update for the Prosigna Breast Cancer Gene Signature Assay. The labeling update is derived from the analysis of data by researchers from the Austrian Breast and Colorectal Cancer Study Group Trial 8, or ABCSG-8, who previously reported that the Prosigna Assay accurately assessed the probability of distant recurrence in postmenopausal women with Estrogen Receptor-Positive, or ER+, early-stage breast cancer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use